MedWatch

ALK raises financial expectations one week before Q2 report drops

The allergy firm says the upgrade is due to a strong sales momentum.

Photo: ALK / PR

During the first half of 2022, allergy firm ALK has beat its own financial targets after ”a strong sales momentum,” which has now resulted in a guidance upgrade, according to a Thursday press release.

ALK is now expecting revenue growth of 10–13% for the full year, its prior prognosis being 8–12%. For the operating profit (EBITDA), which used to be projected at DKK 625–725m (USD 85.6–99.3m), the company is revising its estimate to DKK 675–750m (USD 92.4–102.7m).

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs